At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 55 enrolled
Drug / intervention
BLB-750 Vaccine (Qinghai RG strain)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Phase 4 Study to Evaluate the Immunogenicity and Safety of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
In Brief
A Phase 4 clinical trial evaluating BLB-750 Vaccine (Qinghai RG strain) for Pandemic Influenza Prevention. Completed, enrolled 55 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPandemic Influenza Prevention
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJan 2018
Primary CompletionFeb 2018
TodayJul 2026
First PostedDec 12, 2017
Enrollment StartJan 12, 2018
Primary CompletionFeb 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.6 years ago
Interventions
BLB-750 Vaccine (Qinghai RG strain)biological
BLB-750 Injection